Dark

PCRX
Pacira BioSciences, Inc. Common Stock
stock NASDAQ

At Close

Aug 14, 2026 3:59:57 PM EDT

22.99USD-0.820%(-0.19)644,093

22.86Bid 23.12Ask 0.26Spread

Pre-market

Aug 14, 2026 9:07:30 AM EDT

23.10USD-0.345%(-0.08)261

After-hours

Aug 11, 2026 4:00:30 PM EDT

24.38USD-0.205%(-0.05)0

OverviewOptionsHistoricalExchangesShortsNews

Jan 19, 2022

08:49AM EST Barclays Maintains Overweight on Pacira BioSciences, Raises Price Target to $96 Benzinga

Jan 6, 2022

08:10AM EST Pacira Sees Prelim. FY21 Revenue $540.7M-$541.7M vs $534.7M Est. Benzinga

08:00AM EST Pacira Reports Preliminary Unaudited Total Revenue for 2021 of GlobeNewswire Inc

Jan 3, 2022

08:00AM EST Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will present at the 40th Annual J.P. Morgan Healthcare Conference at 3:00 PM ET on Monday, January 10, 2022. Live audio of the virtual event can be accessed by visiting the Events page of the companys website at investor.pacira.com. A replay of the webcast will also be available for two weeks following the event. GlobeNewswire Inc

Dec 9, 2021

08:00AM EST Pacira BioSciences Announces Closing of $375 Million Five-Year GlobeNewswire Inc

Dec 7, 2021

08:13AM EST Pacira BioSciences Reports Nov. Prelim. Net Product Sales Of EXPAREL, iovera $48M Benzinga

08:00AM EST -- EXPAREL average daily sales for November 2021 - 122% of November 2020 GlobeNewswire Inc

Nov 23, 2021

08:00AM EST Pacira BioSciences to Present at the Piper Sandler 33rd Annual GlobeNewswire Inc

Nov 19, 2021

08:40AM EST -- Adds highly complementary ZILRETTA to Pacira commercial offering -- GlobeNewswire Inc

Nov 10, 2021

08:00AM EST Pacira BioSciences to Present at the Jefferies London Healthcare GlobeNewswire Inc

Nov 9, 2021

11:41AM EST Pacira Biosciences Sees Oct. Net Product Sales $4.3M vs $40.7M In same Month Last Year Benzinga

11:08AM EST Pacira Biosciences Reports Filed Suit Against eVenus For Patent Infringement Benzinga

08:00AM EST Pacira BioSciences Reports Preliminary Net Product Sales of $44.3 GlobeNewswire Inc

Nov 5, 2021

12:14PM EDT Expert Ratings For Pacira BioSciences Benzinga

11:02AM EDT Barclays Maintains Overweight on Pacira BioSciences, Raises Price Target to $92 Benzinga

Nov 4, 2021

12:34PM EDT HC Wainwright & Co. Maintains Buy on Pacira BioSciences, Raises Price Target to $86 Benzinga

Nov 3, 2021

09:19AM EDT Pacira BioSciences Q3 Adj. EPS $0.72 Beats $0.65 Estimate, Sales $127.72M Miss $130.38M Estimate Benzinga

09:19AM EDT The Daily Biotech Pulse: Cerus Climbs On Earnings, Horizon CFO To Retire, Teva Prices Upsized Sustainability-Linked Senior Note Offering Benzinga

09:10AM EDT Earnings Scheduled For November 3, 2021 Benzinga

08:00AM EDT -- Third quarter GAAP net income of $17.7 million and adjusted EBITDA of $48.1 million -- GlobeNewswire Inc

Nov 2, 2021

06:35PM EDT LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Flexion Therapeutics, Inc. - FLXN PR Newswire

10:52AM EDT Pacira BioSciences Reports Notice Of Allowance For New Patent Covering EXPAREL Composition Benzinga

07:30AM EDT -- Patent eligible for Orange Book listing will provide additional protection into 2041 -- GlobeNewswire Inc

Oct 31, 2021

02:24PM EDT The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline Benzinga

Oct 27, 2021

07:30AM EDT Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its third quarter financial results before the open of the U.S. markets on Wednesday, November 3, 2021. Following the release, the company will host a live conference call and webcast at 8:30 a.m. ET. GlobeNewswire Inc

Oct 18, 2021

12:56PM EDT Where Pacira BioSciences Stands With Analysts Benzinga

12:56PM EDT UPDATE: Needham On Pacira Price Target Raise: Firm Positive On Flexion Therapeutics Acquisition Given 'Highly Complementary Asset In Zilretta'; Highlights Exparel's Important Role In 'Changing The Post-Op Pain Management Paradigm' & Iovera's Potential Benzinga

06:39AM EDT Needham Maintains Buy on Pacira BioSciences, Raises Price Target to $84 Benzinga

Oct 12, 2021

08:13AM EDT The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology Benzinga

06:35AM EDT HC Wainwright & Co. Maintains Buy on Pacira BioSciences, Lowers Price Target to $80 Benzinga

Oct 11, 2021

07:45AM EDT Pacira BioSciences, Inc. (PCRX) and Flexion Therapeutics, Inc. (FLXN) announced Monday a definitive agreement pursuant to which Pacira will acquire Flexion for $8.50 per share in cash, plus one non-tradeable contingent value right (CVR) worth up to $8.00 per share in cash. RTTNews

07:30AM EDT Pacira To Buy Flexion For $8.50/shr Cash, Plus One Non-tradeable CVR Worth Up To $8/shrcash RTTNews

07:01AM EDT Pacira BioSciences to Acquire Flexion Therapeutics For $8.50/Share In Cash Plus One Non-tradeable Contingent Value Right Worth Up To $8/Share In Cash Benzinga

07:00AM EDT -- Adds highly complementary ZILRETTA to Pacira commercial offering -- GlobeNewswire Inc

Oct 8, 2021

08:05AM EDT Pacira BioSciences To Host Investor Day On Oct. 15, 2021 In Tampa. Florida Benzinga

08:00AM EDT Pacira BioSciences to Host Investor Day on October 15th, 2021 in GlobeNewswire Inc

Oct 6, 2021

07:33AM EDT The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal Benzinga

Oct 4, 2021

07:32AM EDT Pacira BioSciences Receives Paragraph IV Certification Notice Letter Advising That eVenus Pharmaceutical Laboratories Submitted Abbreviated FDA Seeing Authorization Of EXPAREL Benzinga

07:30AM EDT Pacira BioSciences Notified of Abbreviated New Drug Application GlobeNewswire Inc

Oct 1, 2021

06:39AM EDT Barclays Maintains Overweight on Pacira BioSciences, Lowers Price Target to $91 Benzinga

Sep 30, 2021

07:32AM EDT Pacira Announces Commercial Production Underway With Enhanced EXPAREL Manufacturing Process At Swindon Facility Benzinga

07:30AM EDT Pacira Announces Commercial Production Underway with Enhanced GlobeNewswire Inc

Sep 21, 2021

07:56AM EDT Pacira Publishes Phase 3 Study Of EXPAREL Infiltration In Pediatric Patients Undergoing Spinal Or Cardiac Surgeries RTTNews

07:32AM EDT Pacira Highlights Publication Of Phase 3 Study Of EXPAREL Infiltration In Pediatric Patients Undergoing Spinal or Cardiac Surgeries Benzinga

07:30AM EDT Pacira Announces Publication of Phase 3 Study of EXPAREL GlobeNewswire Inc

Sep 15, 2021

07:34AM EDT Pacira BioSciences Reports Prelim. Net Product Sales Of $42.3M For August 2021 Benzinga

07:30AM EDT -- Expanding EXPAREL utilization continues to drive growth with average daily sales at 109% of August 2020 -- GlobeNewswire Inc

Sep 8, 2021

08:00AM EDT Pacira BioSciences to Present at the H.C. Wainwright 23rd Annual GlobeNewswire Inc

Aug 10, 2021

08:11AM EDT Pacira Biosciences Reports Jul. Net Product Sales Of EXPAREL $40.9M, iovera Sales $1M Benzinga

08:00AM EDT Pacira BioSciences Reports Preliminary Net Product Sales of $42.1 GlobeNewswire Inc

Aug 4, 2021

08:00AM EDT Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will present at the 2021 Wedbush PacGrow Healthcare Virtual Conference at 10:20 AM ET on Tuesday, August 10, 2021. Live audio of the virtual event can be accessed by visiting the Events page of the companys website at investor.pacira.com. A replay of the webcast will also be available for two weeks following the event. GlobeNewswire Inc

06:12AM EDT HC Wainwright & Co. Maintains Buy on Pacira BioSciences, Lowers Price Target to $84 Benzinga

Aug 3, 2021

08:10AM EDT Pacira BioSciences Q2 EPS $0.77 Beats $0.69 Estimate, Sales $135.60M Beat $128.01M Estimate Benzinga

08:00AM EDT -- EXPAREL average daily sales at 178% of the prior year second quarter --- Conference call today at 8:30 a.m. ET -- GlobeNewswire Inc

03:52AM EDT Earnings Scheduled For August 3, 2021 Benzinga

Aug 2, 2021

10:52AM EDT Earnings Outlook For Pacira BioSciences Benzinga

08:01AM EDT Pacira Reports FDA Approval Of Enhanced EXPAREL Manufacturing Process Benzinga

08:00AM EDT -- New 200-liter suite doubles capacity to meet growing EXPAREL demand -- GlobeNewswire Inc

Jul 29, 2021

07:30AM EDT New Analysis Shows iovera Plays a Critical Role in GlobeNewswire Inc

Jul 26, 2021

10:05AM EDT Benzinga's Top Ratings Upgrades, Downgrades For July 26, 2021 Benzinga

05:33AM EDT JP Morgan Upgrades Pacira BioSciences to Overweight, Announces $75 Price Target Benzinga

Jul 20, 2021

07:30AM EDT Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its second quarter financial results before the open of the U.S. markets on Tuesday, August 3, 2021. Following the release, the company will host a live conference call and webcast at 8:30 a.m. ET. GlobeNewswire Inc

Jul 13, 2021

08:13AM EDT Pacira Biosciences Reports Q2 Sales $135.6M Benzinga

08:02AM EDT -- EXPAREL average daily sales at 178% of the prior year for the second quarter and 120% of the prior year for the month of June -- GlobeNewswire Inc

Jun 22, 2021

08:27AM EDT Pacira BioSciences Enters Distribution Agreement With Eurofarma For Commercialization Of EXPAREL In Latin America RTTNews

08:08AM EDT Pacira BioSciences Reports EXPAREL Distribution Deal With Eurofarma In Latin America, No Terms Disclosed Benzinga

08:00AM EDT Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced that it has entered into a distribution agreement with Eurofarma Laboratories S.A. (Eurofarma) for the development and commercialization of EXPAREL (bupivacaine liposome injectable suspension) in Latin America. GlobeNewswire Inc

Jun 8, 2021

08:15AM EDT Pacira BioSciences Reports May Preliminary Unaudited Net Product Sales Of EXPAREL Of $41.2 Mln RTTNews

08:00AM EDT Pacira BioSciences Reports Preliminary Net Product Sales of $42.2 GlobeNewswire Inc

May 26, 2021

09:23AM EDT Pacira BioSciences' Exparel Misses Primary Endpoint In Post-Op Pain Study After Lower Extremity Surgeries Benzinga

08:04AM EDT Pacira BioSciences Says Phase 3 STRIDE Study Did Not Demonstrate Statistical Significance For Primary Endpoint Of Pain Reduction From 0 To 96 Hours For EXPAREL Vs Bupivacaine HCL Benzinga

08:00AM EDT -- Study did not demonstrate statistical significance for primary endpoint of pain reduction from 0 to 96 hours for EXPAREL versus bupivacaine HCl -- GlobeNewswire Inc

May 25, 2021

08:00AM EDT Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will present at the 2021 Jefferies Virtual Healthcare Conference at 9:30 AM ET on Tuesday, June 1, 2021. Live audio of the virtual event can be accessed by visiting the Events page of the companys website at investor.pacira.com. A replay of the webcast will also be available for two weeks following the event. GlobeNewswire Inc

May 18, 2021

08:18AM EDT Pacira: USPTO Issued Notice Of Allowance For Application Serial Number 17/156,400 On EXPAREL RTTNews

08:17AM EDT Pacira BioSciences Announces Notice of Allowance Of New Patent For EXPAREL Benzinga

08:00AM EDT Pacira BioSciences Announces Notice of Allowance of New Patent for GlobeNewswire Inc

May 13, 2021

11:01AM EDT Heron's Non-Opioid, Post-Operative Pain Drug Approved By FDA: Why This Is Important Benzinga

May 12, 2021

08:00AM EDT Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will present at the 2021 RBC Capital Markets Global Healthcare Conference at 10:20 AM ET on Tuesday, May 18, 2021. Live audio of the virtual event can be accessed by visiting the Events page of the companys website at investor.pacira.com. A replay of the webcast will also be available for two weeks following the event. GlobeNewswire Inc

May 11, 2021

08:14AM EDT Pacira BioSciences Reports Preliminary EXPAREL Net Product Sales Of $43.1M And Iovera Net Product Sales Of $1.5M for April 2021 Benzinga

08:00AM EDT Pacira BioSciences Reports Preliminary Net Product Sales of $44.6 GlobeNewswire Inc

May 10, 2021

09:25AM EDT BMO Capital Maintains Market Perform on Pacira BioSciences, Lowers Price Target to $70 Benzinga

May 5, 2021

08:44AM EDT Northland Capital Markets Maintains Market Perform on Pacira BioSciences, Lowers Price Target to $66 Benzinga

May 4, 2021

08:14AM EDT Pacira BioSciences Says Co's 2021 Product Sales 'continue to be negatively impacted by the COVID-19 pandemic' Benzinga

08:10AM EDT The Daily Biotech Pulse: Vaxart Rebounds On Strong Vaccine Data, Pfizer's Beat-And-Raise Quarter, BioLineRx Data Benzinga

08:08AM EDT Pacira BioSciences Q1 Adj. EPS $0.56 Misses $0.63 Estimate, Sales $119.00M Miss $119.28M Estimate Benzinga

08:00AM EDT -- EXPAREL average daily sales at 115% of the prior year first quarter--- Conference call today at 8:30 a.m. ET -- GlobeNewswire Inc

Apr 21, 2021

07:30AM EDT Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its first quarter financial results before the open of the U.S. markets on Tuesday, May 4, 2021. Following the release, the company will host a live conference call and webcast at 8:30 a.m. ET. GlobeNewswire Inc

Apr 20, 2021

07:44AM EDT Pacira Biosciences Makes $3M Convertible Note Investment In Spine BioPharma Benzinga

07:40AM EDT Pacira BioSciences Announces $3 Mln Investment In Spine BioPharma RTTNews

07:31AM EDT Spine BioPharma Announces Investment by Pacira Biosciences PR Newswire

07:30AM EDT -- Supports clinical advancement of lead candidate, Remedisc, for degenerative disc disease -- GlobeNewswire Inc

Apr 15, 2021

07:49AM EDT The Daily Biotech Pulse: Merck Shelves 2 COVID-19 Studies, Bristol-Myers Squibb Gets European Regulatory Nod, InspireMD's Reverse Split Benzinga

Apr 14, 2021

04:01PM EDT Pacira BioSciences Says Seeks Court Injunction To 'Protect Clinical Integrity Of EXPAREL In The Face Of Scientifically Flawed And Misleading Information' Published In Anesthesiology Benzinga

04:00PM EDT Pacira BioSciences Seeks Court Injunction to Protect Clinical GlobeNewswire Inc

Apr 9, 2021

10:11AM EDT Benzinga's Top Ratings Upgrades, Downgrades For April 9, 2021 Benzinga

07:54AM EDT Berenberg Initiates Coverage On Pacira BioSciences with Buy Rating, Announces Price Target of $93 Benzinga

Apr 7, 2021

08:15AM EDT Pacira Q1 Preliminary Net Product Sales $118.7 Mln RTTNews

08:05AM EDT Pacira BioSciences Sees Q1 2021 Net Sales $118.7M Vs $126.8M Est Benzinga

08:00AM EDT Pacira Reports Preliminary Net Product Sales of $118.7 Million for GlobeNewswire Inc

Mar 27, 2021

01:01PM EDT The Week Ahead In Biotech (March 28-April 3): Acadia's Dementia Drug Update, Clinical Readouts, Few Earnings In Holiday-Shortened Week Benzinga

Mar 23, 2021

08:18AM EDT The Daily Biotech Pulse: FDA Approvals For Merck, Pacira And Zealand, Roche-Regeneron Ace Late-Stage COVID-19 Study, AlloVir Appoints Gilead Virology Chief As CEO Benzinga

01:31AM EDT AZN's COVID-19 Jab Shows 79% Efficacy, ZEAL Wins FDA RTTNews

Mar 22, 2021

06:42PM EDT -- EXPAREL is the first and only FDA-approved long-acting local analgesic for children aged six and over -- Conference call tomorrow at 8:30 a.m. ET -- GlobeNewswire Inc

08:40AM EDT Benzinga Pro's Top 5 Stocks To Watch For Monday, Mar. 22, 2021: ADBE, ENG, PCRX, RH, HOTH Benzinga

Mar 9, 2021

08:00AM EST -- EXPAREL average daily sales at 103% of the prior year for the month of February 2021 -- GlobeNewswire Inc

Mar 3, 2021

07:30AM EST Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will present at the 2021 Barclays Global Healthcare Conference at 10:55 AM ET on Tuesday, March 9, 2021. Live audio of the virtual event can be accessed by visiting the Events page of the companys website at investor.pacira.com. A replay of the webcast will also be available for two weeks following the event. GlobeNewswire Inc

Mar 1, 2021

06:58AM EST HC Wainwright & Co. Maintains Buy on Pacira BioSciences, Raises Price Target to $86 Benzinga

Feb 28, 2021

11:38AM EST Attention Biotech Investors: Mark Your Calendar For March PDUFA Dates Benzinga

Feb 26, 2021

08:17AM EST The Daily Biotech Pulse: Adcom Test Awaits J&J's COVID-19 Vaccine, Lilly To Supply Additional Antibody Therapy Doses To US, Regulatory Setback For Tricida Benzinga

Feb 25, 2021

08:08AM EST The Daily Biotech Pulse: Merck Goes Shopping, Decision Day For Sarepta, Pfizer, Moderna Unveil Vaccine Strategies For Coronavirus Variants Benzinga

08:04AM EST Pacira BioSciences Q4 EPS $0.32 Down From $0.56 YoY, Adj. EBITDA $42.9M, Sales $131.00M Miss $131.57M Estimate Benzinga

08:00AM EST Pacira BioSciences Reports Full-Year and Fourth Quarter 2020 GlobeNewswire Inc

04:03AM EST Earnings Scheduled For February 25, 2021 Benzinga

Feb 18, 2021

07:30AM EST Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its fourth quarter and year ended December 31, 2020 financial results before the open of the U.S. markets on Thursday, February 25, 2021. Following the release, the company will host a live conference call and webcast at 8:30 a.m. ET. GlobeNewswire Inc

Feb 11, 2021

11:21AM EST Stocks That Hit 52-Week Highs On Thursday Benzinga

Feb 10, 2021

07:05AM EST Pacira BioSciences Reports Preliminary Net Product Sales For EXPAREL And iovera Were $36M For Jan. 2021 Benzinga

07:00AM EST Pacira BioSciences Reports Preliminary Net Product Sales of $36.0 GlobeNewswire Inc

Jan 26, 2021

08:01AM EST Pacira BioSciences Reports Initial Investment Of 2M With Added 4M Investment Predicated Upon Terms Of Deal For GeneQuine Biotherapeutics Benzinga

08:00AM EST Pacira BioSciences Announces Equity Investment in GlobeNewswire Inc

Jan 21, 2021

10:03AM EST Benzinga's Top Ratings Upgrades, Downgrades For January 21, 2021 Benzinga

08:06AM EST 10 Biggest Price Target Changes For Thursday Benzinga

06:06AM EST SVB Leerink Downgrades Pacira BioSciences to Market Perform, Raises Price Target to $75 Benzinga

Jan 15, 2021

07:57AM EST The Daily Biotech Pulse: DBV's Positive FDA Feedback, Pfizer's Cancer Drug Gets Label Expansion, Applied DNA COVID Testing Volume Surges Benzinga

Jan 14, 2021

07:57AM EST The Daily Biotech Pulse: Alexion Pauses COVID-19 Study, NantKwest Readout, Organogenesis Jumps On Guidance, Trial Updates Benzinga

Jan 13, 2021

07:25AM EST The Daily Biotech Pulse: Bausch Health Issues Positive Pre-Announcement, Acorda Streamlines Operations Benzinga

Jan 12, 2021

08:16AM EST The Daily Biotech Pulse: GSK, Vir To Start COVID-19 Antibody Study, Novartis In-Licenses BeiGene's Cancer Drug, Earnings Preannouncements Continue Benzinga

Jan 8, 2021

07:25AM EST The Daily Biotech Pulse: Sarepta Gene Therapy Study Readout, Novavax Vaccine Supply Deal, 2 IPOs Benzinga

05:19AM EST Needham Maintains Buy on Pacira BioSciences, Raises Price Target to $76 Benzinga

Jan 7, 2021

07:39AM EST Pacira BioSciences Reports FY20 Sales of $429.6M, Up 2% YoY Benzinga

07:30AM EST -- EXPAREL average daily sales at 109% of the prior year for the fourth quarter and 111% of the prior year for the month of December -- GlobeNewswire Inc

Jan 6, 2021

07:30AM EST Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will present at the 39th Annual J.P. Morgan Healthcare Conference at 7:30 AM ET on Wednesday, January 13, 2021. Live audio of the virtual event can be accessed by visiting the Events page of the companys website at investor.pacira.com. A replay of the webcast will also be available for two weeks following the event. GlobeNewswire Inc

Dec 9, 2020

10:38AM EST Needham Maintains Buy on Pacira BioSciences, Lowers Price Target to $67 Benzinga

07:43AM EST Pacira BioSciences November Preliminary Net Product Sales $38.9 Mln RTTNews

07:32AM EST Pacira BioSciences Reports EXPAREL and iovera Preliminary Net Product Sales of $38.9M for November 2020 Benzinga

07:30AM EST -- EXPAREL average daily sales at 103% of the prior year for the month of November 2020 -- GlobeNewswire Inc

Nov 24, 2020

08:13AM EST The Daily Biotech Pulse: Alnylam's Oxluma Snags Early FDA Approval, DBV Chief Scientific Officer To Depart, Decision Day For Liquidia Benzinga

07:30AM EST Pacira BioSciences to Present at the 2020 Piper Sandler 32nd GlobeNewswire Inc

Nov 20, 2020

08:06AM EST The Daily Biotech Pulse: Amarin Surges On Vascepa Data, Mesoblast Rallies On Novartis Deal, Decision Day For Eiger Benzinga

Nov 19, 2020

08:17AM EST The Daily Biotech Pulse: Aquestive's Positive FDA Meeting, Prevail Awarded Patent, Neuro-Oncology Conference Gets Underway Benzinga

Nov 18, 2020

07:33AM EST Pacira Receives European Commission Approval Of EXPAREL For Treatment Of Postsurgical Pain Benzinga

07:30AM EST --Approval based on four pivotal studies showing EXPAREL reduced pain scores and opioid use following surgery-- GlobeNewswire Inc

Nov 17, 2020

08:32AM EST The Daily Biotech Pulse: Setback For Alkermes, Boston Scientific's Recall, ALX-Zymeworks Oncology Collaboration Benzinga

Nov 11, 2020

08:07AM EST Pacira October Preliminary Net Product Sales $41.7 Mln RTTNews

08:06AM EST Pacira Biosciences Sees Oct. Net Product Sales $41.7M Benzinga

08:00AM EST Pacira BioSciences, Inc. (Nasdaq: PCRX), the leading provider of innovative non-opioid pain management options, today reported preliminary unaudited net product sales of EXPAREL (bupivacaine liposome injectable suspension) and iovera of $40.7 million and $1.0 million, respectively, for the month of October 2020. GlobeNewswire Inc

Nov 10, 2020

07:30AM EST Pacira BioSciences to Present at the 2020 Jefferies Virtual London GlobeNewswire Inc

Nov 2, 2020

09:17AM EST Wedbush Maintains Outperform on Pacira BioSciences, Lowers Price Target to $83 Benzinga

Oct 29, 2020

08:17AM EDT Pacira BioSciences Q3 EPS $0.68 Beats $0.61 Estimate, Sales $117.48M Beat $115.15M Estimate Benzinga

08:00AM EDT -- EXPAREL average daily sales at 110% of the prior year for the third quarter-- GlobeNewswire Inc

07:30AM EDT The Daily Biotech Pulse: Novartis Acquires Gene Therapy Company, Moderna's Japanese Vaccine Supply Deal Benzinga

04:08AM EDT Earnings Scheduled For October 29, 2020 Benzinga

Oct 21, 2020

07:30AM EDT --The Pacira Innovation and Training Center of Tampa will provide clinicians with a flexible environment for hands-on learning-- GlobeNewswire Inc

Oct 20, 2020

07:30AM EDT Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its third quarter financial results before the open of the U.S. markets on Thursday, October 29, 2020. Following the release, the company will host a live conference call and webcast at 8:30 a.m. ET. GlobeNewswire Inc

Oct 7, 2020

08:18AM EDT Pacira BioSciences Reports Q3 Prelim. Net Product Sales of $116.9M; Pacira BioSciences Reports Prelim. Net Product Sales Of EXPAREL Were $113.7M And Iovera Were $2.7M Benzinga

08:00AM EDT -- EXPAREL average daily sales at 110% of the prior year for the third quarter and 110% of the prior year for the month of September -- GlobeNewswire Inc

Sep 21, 2020

11:44AM EDT Northland Capital Markets Upgrades Pacira BioSciences to Outperform, Raises Price Target to $67 Benzinga

Sep 18, 2020

08:09AM EDT Pacira BioSciences Reports Positive CHMP Opinion For EXPAREL For Treatment Of Postsurgical Pain Benzinga

08:08AM EDT -- CHMP opinion supported by four pivotal studies showing EXPAREL reduced pain scores and opioid use following surgery-- GlobeNewswire Inc

Sep 15, 2020

07:30AM EDT IPG, the industry-leading provider of surgical cost management solutions, and Pacira BioSciences, Inc. (NADSAQ: PCRX), a leading provider of non-opioid pain management options, today announced a collaboration to reduce postsurgical opioid prescribing and surgical procedure costs across the IPG national health plan and provider network. GlobeNewswire Inc

Sep 11, 2020

07:30AM EDT Pacira BioSciences to Present at the 2020 H.C. Wainwright 22nd GlobeNewswire Inc

Sep 9, 2020

11:26AM EDT Needham Maintains Buy on Pacira BioSciences, Raises Price Target to $68 Benzinga

08:25AM EDT Pacira BioSciences Reports Prelim. Aug. Net Product Sales $36.9M Benzinga

08:00AM EDT -- EXPAREL average daily sales at 111% of the prior year for the month of August 2020 -- GlobeNewswire Inc

Aug 6, 2020

09:26AM EDT Pacira BioSciences Earlier Reported Q2 EPS $0.12 Beats $0.09 Estimate, Sales $75.50M Beat $72.46M Estimate Benzinga

08:00AM EDT -- EXPAREL average daily sales return to year-over-year growth in month of June 2020 --- Conference call today at 8:30 a.m. ET -- GlobeNewswire Inc

Aug 5, 2020

07:43AM EDT Pacira Highlights Publication Of Phase 4 Study Of EXPAREL In Cesarean Section Procedures In Anesthesia & Analgesia Benzinga

07:30AM EDT Results show an opioid-reducing benefit of adding EXPAREL to bupivacaine transversus abdominis plane (TAP) blocks for cesarean delivery GlobeNewswire Inc

Aug 4, 2020

07:49AM EDT Pacira BioSciences Announces FDA Acceptance Of sNDA For EXPAREL Use In Pediatric Patients Benzinga

07:30AM EDT sNDA submission based on positive Phase 3 data supporting expansion of the EXPAREL label to include use in children aged six and over GlobeNewswire Inc

Jul 30, 2020

07:30AM EDT Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its second quarter financial results before the open of the U.S. markets on Thursday, August 6, 2020. Following the release, the company will host a live conference call and webcast at 8:30 a.m. ET. GlobeNewswire Inc

Jul 28, 2020

05:10PM EDT Pacira BioSciences Reports Settlement Of Government Investigation; To Pay $3.5 Mln RTTNews

05:04PM EDT Pacira BioSciences Reports Will Pay $3.5M To Settle Various Claims Related To Gov't. Investigation Benzinga

Jul 13, 2020

08:50AM EDT HC Wainwright & Co. Reiterates Buy on Pacira BioSciences, Raises Price Target to $68 Benzinga